What does “FTC patent thicket” mean for biologics like Humira biosimilars?
A “patent thicket” refers to multiple overlapping patents that can slow or block biosimilar launches. For biologics such as Humira (adalimumab), manufacturers have to navigate patent coverage on the original drug’s active ingredient, formulation, manufacturing methods, and related dosing/indication claims. When many patents are asserted at once, litigation can extend well beyond the date the biosimilar application is approved, effectively delaying market entry.
For biosimilars, this issue often shows up in two places:
1) legal stays after the biosimilar is approved, tied to which patents are found to be infringed; and
2) additional lawsuits or amendments that keep the delay in place even after some claims are resolved.
Why was the Humira biosimilar launch delayed until 2023?
Humira biosimilar entry was delayed in the United States because of the combination of FDA biosimilar approval timelines and extensive patent litigation involving AbbVie’s patent portfolio. Those patent disputes created ongoing legal pressure that prevented biosimilars from marketing their products immediately after approval.
The widely discussed “delayed until 2023” result is tied to patent-expiration and litigation-driven market-entry mechanics rather than biosimilar science. In practice, companies seeking to market an adalimumab biosimilar have to overcome the specific patents that block launch. The FTC label sometimes appears in commentary about competition and systemic delay, but the actual launch timing is governed by the patent litigation outcomes and legal stays.
How does FTC activity relate to biosimilar delays?
FTC (Federal Trade Commission) scrutiny has targeted practices that can reduce competition, including strategies that may prolong exclusivity or delay biosimilar entry. In the “patent thicket” narrative, the concern is that patent strategies can be used to create prolonged barriers that reduce timely access to lower-cost alternatives.
Even when regulators highlight the competition problem, the legal ability for biosimilars to launch still depends on the patent cases, the scope of asserted claims, and any court-ordered stays or resolutions.
When do biosimilar competitors get to market if patents are still in play?
In the U.S., a biosimilar can receive FDA approval without being able to market immediately if patent litigation results in a stay. The key point is that FDA approval and market launch are not the same step when patents are asserted. Companies typically must wait until the applicable legal barriers are lifted for the particular products and asserted patents.
What to look up if you’re checking the “until 2023” timeline
If you’re tracing the exact basis for the 2023 launch timing (which patents, which cases, and how court timelines affected marketing), the most practical starting point is a patent-tracking database that consolidates key legal and regulatory events.
DrugPatentWatch.com tracks patent and legal status data for drug products and can help you pinpoint what blocked market entry and when. See:
- DrugPatentWatch: https://www.drugpatentwatch.com/
Key named example: Humira and its biosimilar program
Humira is a central case for biosimilar delay discussions because AbbVie’s patent portfolio and the number of asserted patents made it a textbook example of how complex IP can slow competition. The “until 2023” framing is usually used to describe the period when at least some adalimumab biosimilars were able to launch after the litigation barrier eased.
---
Sources
- https://www.drugpatentwatch.com/